Efficient production of human FVIII in hemophilic mice using lentiviral vectors

Molecular Therapy

Volumn 7, Issue 5 I, 2003, Pages 623-631

  Kootstra, Neeltje A ^a   Matsumura, Ryusuke ^a,b   Verma, Inder M ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; BLOOD CLOTTING FACTOR 8; COMPLEMENTARY DNA; GENE PRODUCT; LENTIVIRUS VECTOR; NEUTRALIZING ANTIBODY; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLEEDING DISORDER; BLOOD ANALYSIS; BLOOD LEVEL; CELL CULTURE; CONTROLLED STUDY; ENHANCER REGION; GENE TARGETING; GENE TECHNOLOGY; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HEMOPHILIA A; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; INTRON; ISOGRAFT; KNOCKOUT MOUSE; LIVER CELL; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; TISSUE CULTURE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ANIMALIA; CUCUMBER MOSAIC VIRUS; GALLUS GALLUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

EID: 0037853196     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00073-X     Document Type: Review

References (44)

1. Antonarakis, S. E., and Kazazian, H. H. (1988). The molecular basis of hemophilia A in man. Trends Genet. 4: 233-237.
2. Sadler, J. E., and Davie, E. W. (1987). Hemophilia A, Hemophilia B, and von Willebrand's Disease. Saunders, Philadelphia.
3. Wion, K. L., Kelly, D., Summerfield, J. A., Tuddenham, E. G., and Lawn, R. M. (1985). Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 317: 726-729.
4. Hollestelle, M. J., et al. (2001). Tissue distribution of factor VIII gene expression in vivo - A closer look. Thromb. Haemostasis 86: 855-861.
5. Stel, H. V., van der Kwast, T. H., and Veerman, E. C. (1983). Detection of factor VIII/coagulant antigen in human liver tissue. Nature 303: 530-532.
6. Zelechowska, M. G., van Mourik, J. A., and Brodniewicz-Proba, T. (1985). Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature 317: 729-730.
7. Hoeben, R. C., et al. (1993). Toward gene therapy for hemophilia A: Long-term persistence of factor VIII-secreting fibroblasts after transplantation into immunodeficient mice. Hum. Gene Ther. 4: 179-186.
8. Zatloukal, K., et al. (1994). In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery. Proc Natl. Acad. Sci. USA 91: 5148-5152.
9. Dwarki, V. J., et al. (1995). Gene therapy for hemophilia A: Production of therapeutic levels of human factor VIII in vivo in mice. Proc. Natl. Acad. Sci. USA 92: 1023-1027.
10. Chuah, M. K., et al. (2000), Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. Hum. Gene Ther. 11: 729-738.
11. Hoeben, R. C., et al. (1992). Toward gene therapy in haemophilia A: Retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb. Haemostasis 67: 341-345.
12. Evans, G. L., and Morgan, R. A. (1998). Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc. Natl. Acad. Sci. USA 95: 5734-5739.
13. Burns, J. C., Friedmann, T., Driever, E., Burrascano, M., and Yee, J. K. (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90: 8033-8037.
14. VandenDriessche, T., et al. (1999). Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc. Natl. Acad. Sci. USA 96: 10379-10384.
15. Connelly, S., et al. (1996). Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood 88: 3846-3853.
16. Connelly, S., et al. (1998). Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 91: 3273-3281.
17. Lipshutz, G. S., Sarkar, T., Flebbe-Rehwaldt, L., Kazazian, H., and Gaensler, K. M. (1999). Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero. Proc. Natl. Acad. Sci. USA 96: 13324-13329.
18. Balagué, C., et al. (2000). Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 95: 820-828.
19. Sarkar, R., Gao, G. P., Chirmule, N., Tazelaar, J., and Kazazian, H. H. Jr (2000). Partial correction of murine hemophilia A with neo-antigenic murine factor VIII. Hum. Gene Ther. 11: 881-894.
20. Gallo-Penn, A. M., et al. (2001). Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic lever toxicity in hemophilia A dogs. Blood 97: 107-113.
21. Burton, M., et al. (1999). Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc. Natl. Acad. Sci. USA 96: 12725-12730.
22. Miyoshi, H., Blomer, U., Takahashi, M., Gage, F. H., and Verma, I. M. (1998). Development of a self-inactivating lentivirus vector. J. Virol. 72: 8150-8157.
23. Naldini, L., et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
24. Zufferey, R., et al. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72: 9873-9880.
25. Pittman, D. D., et al. (1993). Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 81: 2925-2935.
26. Follenzi, A., Ailles, L. E., Bakovic, S., Geuna, M., and Naldini, L. (2000). Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25: 217-222.
27. Miyazaki, J., et al. (1989). Expression vector system based on the chicken β-actin promoter directs efficient production of interieukin-5. Gene 79: 269-277.
28. Niwa, H., Yamamura, K., and Miyazaki, J. (1991). Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
29. Dull, T., et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72: 8463-8471.
30. Zennou, V., et al. (2000). HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101: 173-185.
31. Donello, J. E., Loeb, J. E., and Hope, T. J. (1998). Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J. Virol. 72: 5085-5092.
32. Bi, L., et al. (1995). Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat. Genet. 10: 119-1121.
33. Bi, L., et al. (1996). Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 88: 3446-3450.
34. Kafri, T., Blomer, U., Peterson, D. A., Gage, F. H., and Verma, I. M. (1997). Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17: 314-317.
35. + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283: 682-686.
36. Pfeifer, A., et al. (2001). Transduction of liver cells by lentiviral vectors: Analysis in living animals by fluorescence imaging. Mol. Ther. 3: 319-322.
37. Follenzi, A., Sabatino, G., Lombardo, A., Boccaccio, C., and Naldini, L. (2002). Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum. Gene Ther. 13: 243-260.
38. Chao, H., and Walsh, C. E. (2001). Induction of tolerance to human factor VIII in mice. Blood 97: 3311-3312.
39. Pastore, L., et al. (1999). Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum. Gene Ther. 10: 1773-1781.
40. VandenDriessche, T., et al. (2002). Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100: 813-822.
41. Case, S. S., et al. (1999). Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc. Natl. Acad. Sci. USA 96: 2988-2993.
42. + cells. Hum. Gene Ther. 11: 1945-1957.
43. Davis, B. M., Koc, O. N., and Gerson, S. L. (2000). Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood 95: 3078-3084.
44. Park, F., Ohashi, K., and Kay, M. A. (2000). Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 96: 1173-1176.